---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-22-000015"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:15:01.735521+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q1 revenue $10.8M (+17% YoY); net loss $15.8M; reaffirms FY 2022 guidance

## Summary
- Worldwide revenue $10.8M, up 17% YoY (20% constant currency); US revenue $6.0M (+40%).
- Net loss $15.8M ($0.43/share) vs. $12.5M loss ($0.35/share) in Q1 2021.
- Gross margin improved to 75% from 72% YoY, driven by production efficiencies.
- Added 16 new US Zephyr Valve treatment centers; total 230 centers.
- FY 2022 outlook unchanged: revenue $55-60M; operating expenses $100-105M.

## SEC filing metadata
- accession: 0001127537-22-000015
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000015/0001127537-22-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000015/lung-20220503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-22-000015
- JSON: https://secwatch.observer/filing/0001127537-22-000015.json
- Plain text: https://secwatch.observer/filing/0001127537-22-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.